Myriad Genetics CEO has shares withheld to cover RSU taxes

Myriad Genetics reported an insider equity event involving its President and CEO, Samraat S. Raha, who is also a director.

Rhea-AI Filing Summary

Myriad Genetics reported an insider equity event involving its President and CEO, Samraat S. Raha, who is also a director. On December 11, 2025, 29,634 shares of common stock were withheld by the company to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, as indicated by transaction code F. The shares were valued using the closing price of Myriad common stock on that date, shown as $7.3 per share. After this tax withholding, Raha beneficially owned 453,104 shares of Myriad common stock in direct ownership. This reflects routine equity compensation and related tax settlement activity.

Insider Trade Summary

Exercise Price or Tax Liability: 29,634 shares

Exercise Price or Tax Liability 1 txn

Insider Raha Samraat S.

Role President and CEO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	29,634	$7.30	$216K

Holdings After Transaction: Common Stock — 453,104 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on December 11, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Myriad Genetics (MYGN) report for Samraat S. Raha?

The company reported that on December 11, 2025, 29,634 shares of Myriad Genetics common stock were withheld by the company from President and CEO Samraat S. Raha to satisfy tax withholding obligations tied to the vesting of restricted stock units.

Was the MYGN CEOs transaction an open-market sale of shares?

The filing states that the 29,634 shares were withheld by the company to satisfy tax withholding obligations in connection with restricted stock unit vesting, rather than describing an open-market purchase or sale.

How many Myriad Genetics shares does Samraat S. Raha own after this transaction?

Following the reported tax withholding transaction, Samraat S. Raha beneficially owned 453,104 shares of Myriad Genetics common stock in direct ownership.

What roles does Samraat S. Raha hold at Myriad Genetics (MYGN)?

Samraat S. Raha is listed as a Director and as an Officer, serving as President and CEO of Myriad Genetics.

What transaction code is used in this Myriad Genetics insider filing?

The transaction is reported with transaction code F, which in this case corresponds to shares withheld by the company to satisfy tax withholding obligations related to restricted stock unit vesting.

At what price were the withheld Myriad Genetics shares valued for tax purposes?

The number of shares withheld was determined using the closing price of Myriad Genetics common stock on December 11, 2025, which is shown in the filing as $7.3 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/12/2025 - 04:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raha Samraat S.

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/11/2025		F		29,634(1)	D	$7.3	453,104	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on December 11, 2025.

Remarks:

	By: Justin Hunter For: Samraat S. Raha	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.